Global Digital Biomanufacturing Market – Industry Trends and Forecast to 2031

Digital Biomanufacturing Market Analysis and Size

According to a recent report, the process of developing a new drug typically spans 10-15 years and requires a substantial investment of USD 1-2 billion. However, despite these significant resources, more than 90% of drug candidates fail at various stages of clinical trials. This high failure rate not only leads to substantial financial losses for biomanufacturers but also hampers the overall efficiency and productivity of the drug development process.

Data Bridge Market Research analyzes that the digital biomanufacturing market which was USD 18.99 billion in 2023, would rocket up to USD 52.04 billion by 2031, and is expected to undergo a CAGR of 13.64% during the forecast period. “Process analytical technology (PAT)” dominates the type of technology segment of the market due to the growing demand for better methods for treatment and diagnosis in patients. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

The digital biomanufacturing refers to the application of digital technologies, such as artificial intelligence, machine learning, big data analytics, and automation, in the field of biomanufacturing. It involves the integration of digital tools and techniques into the biopharmaceutical manufacturing process to improve efficiency, productivity, quality, and regulatory compliance. Digital biomanufacturing encompasses various aspects, including process optimization, real-time monitoring and control, data-driven decision-making, predictive analytics, and advanced manufacturing technologies.

Global  Digital Biomanufacturing Market Dynamics

Drivers

• Increasing Demand for Biopharmaceuticals

The growing demand for biopharmaceutical products, such as monoclonal antibodies, vaccines, and cell therapies, is driving the need for efficient and scalable manufacturing processes. Digital biomanufacturing enables faster and more cost-effective production of these complex biotherapeutics.

• Advancements in Digital Technologies

Rapid advancements in digital technologies, including artificial intelligence, machine learning, and big data analytics, have made it possible to collect, analyze, and interpret vast amounts of data in real-time. This enables better process control, optimization, and decision-making in biomanufacturing, and it is driving the market growth.

Opportunities

• Enhanced process optimization and productivity

Digital biomanufacturing enables the integration of advanced analytics and machine learning algorithms to optimize bioprocesses. By leveraging real-time data monitoring and analysis, manufacturers can identify bottlenecks, optimize parameters, and streamline production workflows. This leads to improved productivity, reduced costs, and increased yield in biomanufacturing operations.

• Adoption of advanced manufacturing technologies

Digital biomanufacturing opens up opportunities for the adoption of advanced manufacturing technologies, such as continuous manufacturing and modular production systems. These technologies offer increased flexibility, scalability, and efficiency in biomanufacturing processes. By integrating digital tools and automation, manufacturers can achieve faster production cycles, reduced downtime, and improved resource utilization.

Restraints/Challenges

• High Initial Investment Cost

Implementing digital technologies and infrastructure for biomanufacturing can require significant upfront investment. This includes acquiring and integrating digital tools, upgrading existing systems, and training personnel. The cost of implementing these technologies and ensuring compatibility with existing infrastructure can act as a barrier for smaller biomanufacturing companies or those with limited budgets.

• Issues with Data Privacy and Security

With the increased use of digital technologies and the collection of large amounts of data in biomanufacturing processes, there is a need for robust data privacy and security measures. Protecting sensitive information, such as intellectual property, proprietary processes, and patient data, is essential to prevent unauthorized access, data breaches, or misuse. Ensuring data privacy and security requires implementing strong encryption methods, access controls, and regular security audits, which can pose challenges for biomanufacturing companies.

This digital biomanufacturing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the digital biomanufacturing market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In June 2023, Kaia Health launched Angela, a HIPAA-compliant, AI-powered voice-based digital care assistant, companion, and guide with the aim to enhance physical therapy experience of the patients
• In March 2023, MindMaze launched a proprietary medical device called Izar across the US and Europe with an aim to improve the hand recovery post-stroke

Global Digital Biomanufacturing Market Scope

The digital biomanufacturing market is segmented on the basis of type of technology, deployment, type of biologics and application. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type of Technology

• Process Analytical Technology(PAT)
• Data Analysis Software(DAS)
• Manufacturing Execution Systems(MES)
• Digital Twins

Deployment

• Cloud-Based
• On-Premises

Type of Biologics

• Antibodies
• Cell and Gene Therapies
• Proteins
• Vaccines
• Others

Application

• Bioprocess Optimization
• Biomanufacturing Process Automation and Control
• Others

Global Digital Biomanufacturing Market Regional Analysis/Insights

The digital biomanufacturing market is analyz ed and market size insights and trends are provided by country, type of technology, deployment, type of biologics and application as referenced above.

The countries covered in the Digital Biomanufacturing market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa.

North America is expected to dominate the digital biomanufacturing market due to the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2024 to 2031 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for diagnosis and treatment procedures, the large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The digital biomanufacturing market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the digital biomanufacturing market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the digital biomanufacturing market.

Competitive Landscape and Digital Biomanufacturing  Market Share Analysis

The digital biomanufacturing market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the digital biomanufacturing market.

Some of the major players operating in the digital biomanufacturing market are:

• AspenTech (U.S.)
• Dassault Systèmes (France)
• FUJIFILM Diosynth Biotechnologies (U.S.)
• GE Healthcare (U.S.)
• Körber (Germany)
• Merck kGA (Germany)
• Sartorius (Germany)
• Thermo Fisher Scientific (U.S.)

SKU-70797